Total-Body Parametric 18F-FDG PET of COVID-19

University of California, Davis1 个研究点分布在 1 个国家目标入组 13 人2021年5月10日

适应症Covid19

干预措施uEXPLORER/mCT

概览

阶段: 不适用
干预措施: uEXPLORER/mCT
疾病 / 适应症: Covid19
发起方: University of California, Davis
入组人数: 13
试验地点: 1
主要终点: BAB permeability assessed
状态: 已完成
最后更新: 上个月

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.

注册库

clinicaltrials.gov

开始日期

2021年5月10日

结束日期

2022年7月6日

最后更新

上个月

研究类型

Interventional

研究设计

Single Group

性别

All

研究者

发起方

University of California, Davis

责任方

Sponsor

入排标准

入选标准

•COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery.
•First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis.
•Ability to understand and willingness to sign an informed consent form.
•Ability to adhere to the study visit schedule and other protocol requirements.
•All persons ≥18 years of age.

排除标准

•Pregnant or lactating women.
•Any condition that would prohibit the understanding or rendering of informed consent.
•Unable to lie supine for 1-hour imaging with PET.
•Prisoners.
•Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.